Table 1.

Effect of ovariectomy and Los on uterine WW, BW, MAP, and plasma corticosterone

Animal group	Uterine WW (g)	Initial BW (g)	Final BW (g)	BW gain (final/initial)	MAP (mm Hg)	Plasma corticosterone (ng/mL)
Sham–Veh	0.15 ± 0.01	259 ± 5.1	290 ± 6.6	1.12 ± 0.01	103 ± 4.2	180 ± 32
Ovx–Veh	0.03 ± 0.002*	265 ± 4.8	338 ± 7.6*	1.28 ± 0.02*	98.1 ± 2.0	238 ± 20
Sham–Los	0.14 ± 0.008	252 ± 2.6	280 ± 3.3	1.11 ± 0.01	90.2 ± 1.7#	186 ± 45
Ovx–Los	0.03 ± 0.001*	264 ± 1.9	328 ± 4.3*	1.24 ± 0.01*	88.3 ± 1.1#	119 ± 42*

Rats were sham-operated (Sham) or ovariectomized (Ovx) at 3 months of age and treated with vehicle (Veh) or losartan (Los) for 10 weeks before the animals were euthanized and uterine WW, BW, MAP, and plasma corticosterone were determined. For uterine WW and BW: Sham–Veh (n = 14), Ovx–Veh (n = 12), Sham–Los (n = 14), and Ovx–Los (n = 12). For MAP: Sham–Veh (n = 6), Ovx–Veh (n = 6), Sham–Los (n = 12), and Ovx–Los (n = 12). For plasma corticosterone: Sham–Veh (n = 10), Ovx–Veh (n = 10), Sham–Los (n = 10), and Ovx–Los (n = 10). *p < 0.05 vs Sham, same treatment (Student’s t test); ^#p < 0.05 vs. vehicle, same surgery (Student’s t test). Regardless of treatment, ovariectomy decreased WW (p < 0.0001 by two-way ANOVA (surgery, treatment) F = 248; DFn = 1; DFd = 48) and increased BW gain (p < 0.0001 by two-way ANOVA (surgery, treatment), F = 131; DFn = 1; DFd = 56). Losartan reduced the MAP in both Sham and Ovx rats (p < 0.0001 by two-way ANOVA (surgery, treatment) F = 30.1; DFn = 1; DFd = 32)